Companies: 10,795·Total market cap: $144.5T
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNONASDAQHealthcare
$53.01
+$0.00(+0.00%)
Market Cap$2.8B
P/E Ratio
52W High$90.3199
52W Low$29.43
Overview

Soleno Therapeutics, Inc. (SLNO) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

slno · stock forecast · 13 analysts (3M) · FMP · updated May 20, 2026

Analyst Rating & Consensus

Based on 13 Wall Street analysts in the past 3 months

SellBuy

Buy

13 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
8
Hold
5
Sell
0
Strong Sell
0
Total: 13 · Buy rate: 61.5%

12-Month Price Target

High

$107

Consensus

$80.00

+50.9% upside

Low

$53.00

Median: $80 · Last Close: $53.01

The Soleno Therapeutics, Inc. (SLNO) analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month SLNO price target is $80.00, representing +50.9% upside from the current price of $53.01.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $80 (50.9%)

Consensus Target

$80.00

50.9% upside

High Target

$107

101.8%

Low Target

$53

-0.0%

Current Price

$53.01

as of today

Based on analyst price targets, the SLNO stock price prediction for the next 12 months ranges from $53 to $107. The consensus SLNO price forecast of $80.00 implies 50.9% upside from the current price of $53.01.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$52.810.38%

1-day model range: $52.8–$52.82. Peak: $52.82 (-0.38%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$57+6.7%
2028$59+11.0%
2029$60+13.7%
2030$61+15.4%
2031+16.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%0%7%
13Buy
0Neutral
1Sell
RSI (14)93.1Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · SLNO · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$52.98BUY
MA 10$52.96BUY
MA 20$52.87BUY
MA 50$45.79BUY
MA 100$43.89BUY
MA 200$52.40BUY
Current $SLNO · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$52.99BUY
EMA 10$52.91BUY
EMA 20$52.08BUY
EMA 50$48.53BUY
EMA 100$47.77BUY
EMA 200$50.82BUY
Current $SLNO · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wells Fargo2026-04-17
Downgrade ↓
OverweightEqual Weight
HC Wainwright & Co.2026-04-08
Downgrade ↓
BuyNeutral
Wolfe Research2026-04-07
Downgrade ↓
OutperformPeer Perform
TD Cowen2026-04-07
Downgrade ↓
BuyHold
Cantor Fitzgerald2026-04-06
Downgrade ↓
OverweightNeutral
Oppenheimer2026-03-18
Maintains
OutperformOutperform
HC Wainwright & Co.2026-03-04
Maintains
BuyBuy
Wells Fargo2026-02-27
Maintains
OverweightOverweight
TD Cowen2026-02-26
Maintains
BuyBuy
Wells Fargo2026-01-20
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Soleno Therapeutics, Inc. (SLNO) stock. Of the recent 46 rating actions, 0 were upgrades and 5 were downgrades. 13 analysts currently cover SLNO.

Analyst Recommendation Trends

Buy ratings404
Hold ratings05↑ +5
Sell ratings00

SLNO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$462M

↓ 53.0% YoY

Revenue Next Year

$688M

↑ 48.9% YoY

EPS This Year

$3.81

EPS Next Year

$6.14

↑ 61.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast SLNO EPS of $3.81 for the current fiscal year, based on estimates from 7 analysts. The SLNO revenue forecast is $462M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The SLNO stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SLNO price target is $80.00 (+50.9% upside), with an analyst consensus of Buy.

The SLNO short-term stock prediction for tomorrow is $52.81 (-0.38%). The SLNO stock price prediction for 2027 estimates an average of $57. The SLNO stock prediction for 2030 projects a range of $61–$61.

Soleno Therapeutics, Inc. trades on NASDAQ under the ticker SLNO. The SLNO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 62% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

SLNO forecast · 8 questions

According to 13 Wall Street analysts, the average 12-month SLNO price target is $80.00, with a high forecast of $107.00 and a low of $53.00. The median price target is shown in the chart above when available. This implies +50.9% potential upside from the current price of $53.01.

SLNO price targetWhat is SLNO price targetSLNO analyst price targetSLNO 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.